Baxter Q1 Revenue Jumps 3%, Beats Estimates; Adjusted EPS Also Tops Forecasts
Summary
Baxter International reported strong first-quarter results, with revenue rising 3% to $2.70 billion, surpassing analyst expectations of $2.62 billion. The company also beat on the bottom line, posting adjusted diluted EPS of $0.37 against a consensus of $0.31. While organic revenue saw a slight 1% decline due to lower U.S. sales and segment headwinds, the overall beat on both top and bottom lines is a positive signal for the company's operational performance. This earnings release also reiterated the full-year 2026 adjusted EPS guidance of $1.85 to $2.05, which was previously announced. Traders will likely react positively to the Q1 beats, indicating better-than-expected execution despite some underlying challenges.
At the time of this announcement, BAX was trading at $17.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.7B. The 52-week trading range was $15.73 to $32.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.